Friend Reed, Bhutani Manisha, Voorhees Peter M, Usmani Saad Z
Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.
Drug Des Devel Ther. 2017 Mar 20;11:893-900. doi: 10.2147/DDDT.S98053. eCollection 2017.
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.
埃罗妥珠单抗是首批被批准用于治疗多发性骨髓瘤的单克隆抗体之一。它是一种人源化免疫球蛋白Gκ（IgGκ）抗体，靶向信号淋巴细胞激活分子家族成员7（SLAMF7），这是一种在正常和恶性浆细胞上高度表达的表面标志物。本综述总结了促成埃罗妥珠单抗获批的临床前和临床数据，并讨论了正在进行的和未来的临床研究。
